Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Latest From Genmab A/S

M&A Activity During Q2 Declined In Volume And Valuation

Following a pair of $10bn+ deals in Q4 2023 and a $16.5bn takeout in Q1, the second quarter saw no acquisition priced as high as $5bn, Evaluate notes. Aggregate deal volume and values dropped from Q1.

Evaluate Data M & A

Sutro Works Toward A Better Ovarian Cancer ADC

Sutro Biopharma CEO Bill Newell spoke with Scrip about the company’s novel platform, its goal of improving folate receptor alpha-driven ovarian cancer and its business development strategy.

BIO Cancer

Lilly Adds To Radiopharma Arsenal With Option To Buy Radionetics

Lilly paid $140m up front for an option to acquire Radionetics for $1bn within an undisclosed timeframe. The private firm is developing small molecule GPCR-targeted radiopharmaceuticals.

Deals Cancer

Poland’s Quiet Pivot From Generics To Innovative Treatments

Poland is slowly expanding beyond its position as a central European generics hub. More established companies are adding innovative medicine pipelines and a small number of biotechs are making international deals.

Poland Emerging Markets
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Biotechnology
    • Large Molecule
      • Antibodies
UsernamePublicRestriction

Register